Metraipolis › archive › dc_a2af0ecbe1e5

Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer — Europe PMC PMID:41145733

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41145733
DOI
10.1038/s41598-[numero omesso]-5
License (as archived)
solo-consultazione
Archived
2026-11-09T01:08:12.987Z
SHA-256 of the archived text
a664355a077c3351fe4e727fb0c18330b03c8327fd8fff4652f27e121663c557
Stable URL of this page
https://metraipolis.com/documento/dc_a2af0ecbe1e5

How to cite

Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer — Europe PMC PMID:41145733 — Europe PMC (en), https://europepmc.org/article/MED/41145733 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a2af0ecbe1e5 (Metraipolis archive dc_a2af0ecbe1e5, sha256 a664355a077c3351fe4e727fb0c18330b03c8327fd8fff4652f27e121663c557)
BibTeX
@misc{dca2af0ecbe1e5,
  title = {Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer — Europe PMC PMID:41145733},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41145733},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a2af0ecbe1e5; sha256 a664355a077c3351fe4e727fb0c18330b03c8327fd8fff4652f27e121663c557},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41145733. Agents can read the archived copy with the MCP tool read_document.